ORIGINAL RESEARCH

Modified Glasgow Prognostic Score is Better for Predicting Oncological Outcome in Patients with Soft Tissue Sarcoma, Compared to High-Sensitivity Modified Glasgow Prognostic Score

Tomoki Nakamura (1), Kunihiro Asanuma, Tomohito Hagi, Akihiro Sudo

Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, 514-8507, Japan

Correspondence: Tomoki Nakamura, Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie, 514-8507, Japan, Tel +81592315022, Fax +81592315211, Email tomoki66@clin.medic.mie-u.ac.jp

Background: Inflammation plays a critical role in the development, progression, clinical presentation, and diagnosis of tumours. We compared the usefulness of the high-sensitivity modified Glasgow prognostic score (HS-mGPS) and mGPS in predicting oncological outcomes in patients with soft tissue sarcomas (STSs) who underwent primary surgical tumour resection.

Methods: Between 2002 and 2018, 144 patients were included in the study. The mean age of the patients was 63 years. The mean follow-up period was 76 months.

Results: The disease-specific survival (DSS) at five years was 71.5% in all patients. When patients were divided into three groups according to the HS-mGPS and mGPS, those with a score of 1 or 2 had a poorer DSS than those with a score of 0, respectively. When we compared the survival rate among the 98 patients with both HS-mGPS and mGPS of 0 and 21 patients with HS-mGPS of 1 and mGPS of 0, there was no significant difference in the prognosis. In multivariate analysis, larger tumour size and higher mGPS remained significant.

Conclusion: mGPS is a reliable system for identifying patients at high risk for death in patients with STSs.

Keywords: soft tissue sarcoma, modified Glasgow prognostic score, high-sensitivity modified Glasgow prognostic score, oncological outcome, C-reactive protein, albumin

Introduction

Soft tissue sarcoma (STS) is a rare and heterogeneous tumour.¹ The incidence of STS is fewer than 6 per 100,000 cancer cases, accounting for 1–2% of all cancer cases in adults.¹ Lung metastasis develops in 20–50% of STS patients, and the subsequent prognosis is poor.² Inflammation plays a critical role in the development, progression, clinical presentation, and diagnosis of tumours.^{3,4} In cancer patients, inflammation is closely related to nutrition; inflammation induces malnutrition by increasing catabolism and impairing nutrient absorption; conversely, malnutrition promotes the severity of inflammation.^{5,6} Therefore, the combination of hypoalbuminaemia (< 3.5 g/dl) and elevated C-reactive protein (CRP) (> 1.0 mg/dl) levels, which is used to calculate the Glasgow prognostic score (GPS), is an important indicator.⁷ The modified GPS (mGPS) highlights the importance of CRP; when CRP is elevated, patients with normal albumin levels are assigned a score of 1.⁸ Recently, some authors have suggested that a lower threshold for CRP (> 0.3 mg/dl) may enhance the prognostic value of mGPS in patients with cancer, and a high-sensitivity modified GPS (HS-mGPS) has been proposed.⁹ Previous studies have shown the utility of the HS-mGPS in predicting the survival of patients with STSs, ^{10,11} although the relationship between mGPS and survival in patients with STSs has not been reported due to the high threshold of CRP levels. In this study, we compared the usefulness of the HS-mGPS and mGPS in predicting oncological outcomes in patients with STSs who underwent primary surgical tumour resection with a minimum of one year follow-up after surgery.

Materials and Methods

Data Source

This study was approved by Mie University Hospital (H2020-224). Informed consent was obtained from all the patients. procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 1983. Data from 2002 to 2018 were retrospectively reviewed. Patients presenting with recurrent disease, metastases, and those referred for additional resection after a previous inappropriate excision were excluded from this study. We further excluded dermatofibrosarcoma protuberans and well-differentiated liposarcoma. Finally, 144 patients (88 men and 56 women) were included in the study. The mean age of the patients was 63 years (range 21-89 years). The tumours were located in the thigh (n = 60), leg (n = 18), buttock (n = 12), upper arm (n = 10), chest wall (n = 9), back (n = 9), forearm (n = 5), inguinal lesion (n = 5), and other sites (n = 16), including three retroperitoneal lesions. The mean follow-up period was 76 months (range 1–203 months). All patients underwent pretreatment staging with CT scans of the lungs to exclude metastases. The histological diagnosis and grade of the tumour were determined using the French Federation of Cancer Centers Sarcoma Group grading system. Serum albumin and CRP levels were obtained prior to treatment inclusing surgery, radiotherapy, and chemotherapy for all patients and were measured using a Denka Seiken X-2 autoanalyzer (Denka Seiken Co., Ltd., Tokyo, Japan). mGPS score was calculated as previously described.⁸ Briefly, patients with both hypoalbuminaemia (< 3.5 g/dl) and an elevated CRP level (> 1.0 mg/dl) were allocated a score of 2. Those who had only an elevated CRP level were assigned a score of 1. The remaining patients were allocated a score of 0. Further, the HSmGPS was calculated as described previously.⁹ Briefly, patients with both hypoalbuminaemia (< 3.5 g/dl) and an elevated CRP level (> 0.3 mg/dl) were allocated a score of 2. Those who had only an elevated CRP level were assigned a score of 1. The remaining patients were allocated a score of 0. The primary purpose of this study was to elucidate the role of the mGPS and HS-mGPS in predicting oncological outcomes in patients with STS.

Statistical Analyses

Statistical associations between the clinicopathological variables were evaluated using the

Kruskal–Wallis rank-sum test for quantitative data and chi-square test for qualitative data. Survival time was measured from the date of surgery of the primary tumour to the date of sarcoma-related death or the last follow-up. Disease-free time was measured from the date of surgery of the primary tumour to the date of local recurrence and/or metastasis. Survival curves were generated using the Kaplan-Meier method and compared using the Log rank test. Univariate and multivariate analyses were performed using Cox proportional hazards regression models. Variables with a p-value < 0.05 in the univariate analyses were included in the multivariate analysis.

All statistical analyses were performed using the EZR graphical user interface (Saitama Medical Center, Jichi Medical University, Saitama, Japan) for R (R Foundation for Statistical Computing, Vienna, Austria), which is a modified version of R Commander designed to add statistical functions frequently used in biostatistics.

Results

The mean tumour size was 8.9 cm (range, 2–30 cm). The depth of the tumours was superficial in 29 patients and deep in 115 patients. Thirteen patients had grade 1 STSs, 44 had grade 2, and 87 had grade 3 STSs. The STSs were classified histologically as follows: 31 malignant fibrous histiocytomas (MFH) or undifferentiated pleomorphic sarcomas (UPS), 30 liposarcomas (15 myxoid type, 13 dedifferentiated type, and 2 pleomorphic type), 29 myxofibrosarcomas, 23 leiomyo-sarcomas, 8 malignant peripheral nerve sheath tumours, 7 synovial sarcomas, and 16 other STSs. All patients underwent primary surgical tumour resection. A total of 10 patients (7%) received adjuvant radiotherapy postoperatively, and 32 patients (22%) received perioperative chemotherapy. Radiotherapy was administered to patients having tumours with inadequate margin. Serum levels of albumin and CRP were measured before chemotherapy in these patients. The mGPS varied from 0 to 2. A total of 19 patients (82.6%) had a score of 0, 19 (13.2%) had a score of 1, and 6 (4.2%) had a score of 2. The HS-mGPS varied from 0 to 2. A total of 98 patients (68%) had a score of 0, 39 (27.1%) had a score of 1, and 7 (4.9%) had a score of 2. Therefore, of the 119 patients with an mGPS of 0, 21 patients had an HS-mGPS of 1. The

relationship between the mGPS, HS-mGPS, and clinicopathological variables is shown in Table 1. The tumour size was related to the scoring system.

Disease-Specific Survival and Prognostic Variables

At the final follow-up, 92 patients (63.9%) were alive, while 44 (30.6%) had died of STSs, and 8 (5.5%) had died of other causes. The disease-specific survival (DSS) at five years was 71.5% (95% confidence interval (CI), 62.7-78.6). When patients were divided into three groups according to the HS-mGPS, those with a score of 1 or 2 had a poorer DSS than those with a score of 0 (p = 0.00174 and p < 0.0001, respectively, Log rank test) (Figure 1). The 5-year DSS rates were 82.7% (95% CI, 72.9-89.3) for those with a score of 0, compared with 51.6% (95% CI, 33.6-67) and 28.6% (95% CI, 4.1–61.2), respectively, for those with scores of 1 and 2. There was a marginally significant difference in the prognosis between patients with scores of 1 and 2 (p = 0.0592, Log rank test). Next, when the patients were divided into three groups according to the mGPS, those with a score of 1 or 2 had a poorer DSS than those with a score of 0 (p < 10.0001 and p < 0.0001, respectively, Log rank test). There was no significant difference in the prognosis between patients with scores of 1 and 2 (p = 0.185, Log rank test) (Figure 2). Finally, when we compared the survival rate among the 98 patients with both HS-mGPS and mGPS of 0 and 21 patients with HS-mGPS of 1 and mGPS of 0, there was no significant difference in the prognosis (p = 0.402, Log rank test) (Figure 3). Patients with an mGPS of 1 or 2 had a poorer DSS than the 98 patients with both HS-mGPS and mGPS of 0 (p < 0.0001 and p < 0.0001, respectively, Log rank test), and 21 patients with HS-mGPS of 1 and mGPS of 0 (p = 0.0336 and p < 0.0001, respectively, Log rank test). In univariate analysis, larger tumour size, grade 3 STSs, and higher mGPS were independent prognostic variables for predicting DSS. In multivariate analysis, larger tumour size and higher mGPS remained significant (Table 2).

Disease-Free Survival and Prognostic Variables

As an initial relapse, a total of 30 patients (20.8%) developed local recurrence. A total of 46 patients (31.9%) developed metastases. The disease-free survival (DFS) rate at 5 years was 53.6% (95% CI, 45–61.6). When the patients were divided into three groups according to the HS-mGPS, those with a score of 1 or 2 had a poorer DFS than those with a score of 0 (p = 0.00314, p < 0.0001, respectively, Log rank test) (Figure 4). The 5-year DFS rate was 63.7% (95% CI, 53–72.6) for those with a score of 0, compared with 35.9% (95% CI, 21.4–50.6) and not reached for those with scores of 1 and 2. There was no significant difference in the prognosis between patients with scores of 1 and 2 (p = 0.0835, Log

Variables			p value				
	mGPS HS-mGPS	0 0	0 I	I I	2 2		
	n	98	21	19	6		
Age	Mean	65.5	67	62	70	0.482*	
	Range	21 to 89	43 to 86	32 to 87	63 to 80		
Sex	Male	56	16	14	2	0.118	
	Female	42	5	5	4		
Depth	Superficial	23	2	4	0	0.299	
	Deep	75	19	15	6		
Size	Mean	7	8	10	14.5	0.0127*	
	Range	2 to 30	4 to 27	2 to 23	7.5 to 18		
Grade	I	12	I	0	0	0.073	
	2	35	5	4	0		
	3	51	15	15	6		

Table I The Relationship Between mGPS, HS-mGPS and Clinical Date

Note: *Kruskal-Wallis rank sum test, others: chi-square test.

Abbreviations: mGPS, modified Glasgow prognostic score; HS-mGPS, High sensitivity modified Glasgow prognostic score.




Figure I Kaplan-Meier curve showing the disease-specific survival according to the HS-mGPS score.




Figure 2 Kaplan-Meier curve showing the disease-specific survival according to the mGPS score.





Figure 3 Kaplan-Meier curve showing disease specific survival. (a: patients who had both HS-mGPS and mGPS score of 0, b: patients who had HS-mGPS score of 1 and mGPS score of 1, c: patients who had mGPS score of 1, d: patients who had mGPS score of 2).


rank test). Next, when patients were divided into three groups according to the mGPS, those with a score of 1 or 2 had a poorer DFS than those with a score of 0 (p < 0.0001 and p < 0.0001, respectively, Log rank test). There was no significant difference in the prognosis between patients with scores of 1 and 2 (p = 0.135, Log rank test) (Figure 5). The

Variables		Univariate Analysis			Multivariate Analysis			
		HR	95% CI	p value	HR	95% CI	p value	
Age	Years	1.02	0.997 to 1.043	0.0845				
Sex	Female	1						
	Male	0.863	0.473 to 1.575	0.631				
Depth	Deep	1						
	Superficial	0.893	0.428 to 1.863	0.762				
Size	cm	1.112	1.06 to 1.166	<0.0001	1.084	1.025 to 1.147	0.00485	
Grade	l or 2	1			1			
	3	2.502	1.26 to 4.965	0.00876	1.858	0.914 to 3.779	0.0872	
Cx	No							
	Yes	1.623	0.86 to 3.063	0.135				
mGPS	0	1			1			
	I	3.984	2.006 to 7.913	<0.0001	2.812	1.379 to 5.732	0.00444	
	2	8.596	3.231 to 22.87	<0.0001	3.876	1.357 to 11.07	0.0114	
HS-mGPS	0	1						
	I	2.63	1.4 to 4.942	0.00265				
	2	7.566	2.783 to 20.57	<0.0001				
mGPS and HS-	а	I.						
mGPS	b	1.451	0.585 to 3.6	0.422				
	с	4.278	2.093 to 8.744	<0.0001				
	d	9.242	3.402 to 25.11	<0.0001				

Table 2 The Prognostic Factors for Disease Specific Survival in 144 Patients

Notes: a: both HS-mGPS and mGPS score of 0, b: HS-mGPS score of 1 and mGPS score of 1, c: mGPS score of 1, d: mGPS score of 2. Abbreviations: Cx, perioperative chemotherapy; mGPS, modified Glasgow prognostic score; HS-mGPS, High sensitivity modified Glasgow prognostic score; 95% CI, 95% confidential interval; HR; Hazard ratio.









Figure 5 Kaplan-Meier curve showing the disease-free survival according to the mGPS score.


5-year DFS rate was 62.5% (95% CI, 52.9–70.7) for those with a score of 0, compared with 15.8% (95% CI, 3.92–34.9) and not reached, respectively, for those with a score of 1 and 2. Finally, when we compared survival among the 98 patients with HS-mGPS and mGPS of 0 and 21 patients with HS-mGPS of 1 and mGPS of 0, there was no significant

difference in the prognosis (p = 0.859, Log rank test) (Figure 6). Patients with an mGPS of 1 or 2 had a poorer DSS than the 98 patients with both HS-mGPS and mGPS of 0 (p < 0.0001 and p < 0.0001, respectively, Log rank test), and 21 patients with HS-mGPS of 1 and mGPS of 0 (p = 0.00263 and p < 0.0001, respectively, Log rank test) (Figure 6). In univariate analysis, larger tumour size, higher age, grade 3 STSs, and higher mGPS were independent prognostic variables for predicting DSS. In the multivariate analysis, all the variables remained significant (Table 3).

Discussion

The association between systemic inflammation and poor prognosis has previously been reported in patients with STSs.^{10–14} In the cancer microenvironment, inflammation contributes to the promotion of cancer cell proliferation, invasion, and metastatic spread.^{3,4} As a systemic inflammation marker, CRP is a reliable marker for predicting oncological outcomes in several cancers, including STS.^{12–15} Additionally, serum albumin levels are a leading indicator of nutritional status, and serum albumin levels likely decrease secondarily to a systemic inflammatory response.^{5,6,16} GPS or mGPS has been shown to provide additional prognostic information in patients with several types of cancers.^{7,8} However, the ability of mGPS to predict poor prognoses is restricted because only a few patients show abnormal mGPS when a CRP cut-off value of 1.0 mg/dl is used. Therefore, subsequent studies further refined mGPS to HS-mGPS using a lower threshold for CRP to enhance the predictive ability of inflammation-based prognostic systems in cancer patients.^{9–11,17,18} When a lower cut-off value for CRP in the HS-mGPS scoring system was used, the number of patients with abnormal scores increased. In this study, 46 patients (31.9%) had HS-mGPS of 1 or 2, although only 25 (17.4%) had an mGPS of 1 or 2. Hou et al reported that the HS-mGPS was an independent predictor of survival in 454 patients with STSs.¹¹ In their cohort, only 77 (17%) patients had an mGPS of 1 or 2. However, when the HS-mGPS was used, 152 patients (33.5%) had HS-mGPS of 1 or 2. They used HS-mGPS for further analysis to elucidate the prognostic variables due to the small number of patients with abnormal mGPS scores. Nakamura et al reported that only 31 of 139 patients (22.3%) with STSs had HS-mGPS of 1 or 2, and they concluded that HS-mGPS was a useful scoring system for predicting oncological outcomes.¹⁰ In this study, we also found that HS-mGPS is a useful scoring system for predicting DSS and DFS. However, we wondered if patients with low abnormal levels of CRP (HS-mGPS of 1 and mGPS of 0) had poor oncological outcomes; we found that these patients did not have poorer DSS and DFS than those with normal CRP





Variables		Univariate Analysis			Multivariate Analysis			
		HR	95% CI	p value	HR	95% CI	p value	
Age	Years	1.022	1.004 to 1.039	0.0134	1.021	1.003 to 1.04	0.0192	
Sex	Female	I.						
	Male	1.004	0.628 to 1.607	0.986				
Depth	Deep	I.						
	Superficial	0.599	0.322 to 1.115	0.106				
Size	cm	1.108	1.064 to 1.154	<0.0001	1.068	1.018 to 1.121	0.00714	
Grade	l or 2	I.			I.			
	3	2.566	1.517 to 4.341	0.00044	2.063	1.196 to 3.558	0.00924	
Cx	No	I.						
	Yes	1.58	0.959 to 2.604	0.0727				
mGPS	0	I.			I.			
	1	3.768	2.149 to 6.606	<0.0001	2.879	1.55 to 5.347	0.000816	
	2	8.264	3.438 to 19.87	<0.0001	3.457	1.349 to 8.861	0.0098	
HS-mGPS	0	I.						
	1	2.056	1.258 to 3.359	0.00401				
	2	4.957	2.08 to 11.82	0.000304				
mGPS and HS-mGPS	а	I.						
	b	1.064	0.518 to 2.186	0.867				
	с	3.808	2.141 to 6.772	<0.0001				
	d	8.353	3.443 to 20.27	<0.0001				

 Table 3 The Prognostic Factors for Disease-Free Survival in 144 Patients

Notes: a: Both HS-mGPS and mGPS score of 0, b: HS-mGPS score of 1 and mGPS score of 1, c: mGPS score of 1, d: mGPS score of 2. Abbreviations: Cx, perioperative chemotherapy; mGPS, modified Glasgow prognostic score; HS-mGPS; High sensitivity modified Glasgow prognostic score; 95% CI, 95% confidential interval; HR, Hazard ratio.

levels. These results suggest that mGPS may be a better predictor of survival and relapse than HS-mGPS in patients with STSs who underwent primary surgical tumour resection. We emphasise that patients with an mGPS of 1 or 2 are at risk of relapse and death. Recently, Spence et al reported that prognosis of localized STS strongly correlates with mGPS, as an increasing score was associated with a poorer outcome at international multicentre study.¹⁹ Although there were no reports comparing mGPS and HS-mGPS, mGPS may become a common tool for predicting survival in patients with STS. We also found that tumour size, tumour histological grade, and age were related to survival and/or relapse. When patients have an mGPS of 0, the variables that have been reported as prognostic variables should be taken into consideration during the follow-up after surgery.²⁰

This study has some limitations. First, we focused on the preoperative assessment of the scoring system and its derivatives, without evaluating the postoperative changes. Second, although all patients had pretreatment staging with CT scans of the chest and routine blood tests to rule out the presence of metastases or inflammatory disease, other chronic conditions were not taken into consideration because of the lack of information. Third, we cannot focus the individual histology due to the limitation of the number of this study. Finally, the retrospective nature of the study is another limitation. However, we believe that mGPS is a reliable system for identifying patients at high risk for death and relapse in patients with STSs.

Ethics

This study was approved by the institutional review boards of the authors' affiliated institutions (1310).

Disclosure

The authors report no conflicts of interest in this study.

References

- 1. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. *N Engl J Med.* 2005;353:701–711. doi:10.1056/NEJMra041866
- Nakamura T, Asanuma K, Takao M, et al. Clinical outcome in patients with soft tissue sarcoma who received metastasectomy and/or radiofrequency ablation: Tokai Musculoskeletal Oncology Consortium study. *Cancer Manag Res.* 2021;13:8473–8480. doi:10.2147/CMAR.S333721
- Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature*. 2008;454(7203):436–444. doi:10.1038/nature0720
 Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. *Lancet Oncol*. 2014;15(11):e493–e503.
- doi:10.1016/S1470-2045(14)70263-3
- 5. Baracos VE, Martin L, Korc M, et al. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4(1):17105. doi:10.1038/nrdp.2017.105
- Eckart A, Struja T, Kutz A, et al. Relationship of nutritional status, inflammation, and serum albumin levels during acute illness: a Prospective Study. Am J Med. 2020;133(6):713–722.e7. doi:10.1016/j.amjmed.2019.10.031
- 7. Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. *Br J Cancer*. 2003;89(6):1028–1030. doi:10.1038/sj.bjc.6601242
- 8. McMillan DC, Crozier JE, Canna K, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. *Int J Colorectal Dis.* 2007;22(8):881–886. doi:10.1007/s00384-006-0259-6
- 9. Takeno S, Hashimoto T, Shibata R, et al. The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor in patients with resectable gastric cancer. *Oncology*. 2014;87(4):205–214. doi:10.1159/000362601
- Nakamura T, Matsumine A, Asanuma K, et al. The value of high-sensitivity modified Glasgow prognostic score in predicting the survival of patients with a soft-tissue sarcoma. *Bone Joint J.* 2015;97-B(6):847–852. doi:10.1302/0301-620X.97B.35098
- 11. Hou T, Guo T, Nie R, et al. The prognostic role of the preoperative systemic immune-inflammation index and high-sensitivity modified Glasgow prognostic score in patients after radical operation for soft tissue sarcoma. *Eur J Surg Oncol.* 2020;46(8):1496–1502. doi:10.1016/j. ejso.2020.05.026
- 12. Nakamura T, Matsubara T, et al. Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. *Cancer*. 2012;118(4):1055–1061. doi:10.1002/cncr.26353
- Nakamura T, Grimer R, Gaston C, et al. The value of C-reactive protein and comorbidity in predicting survival of patients with high grade soft tissue sarcoma. Eur J Cancer. 2013;49(2):377–385. doi:10.1016/j.ejca.2012.09.004
- 14. Wang X, Liu S, Zhao X, et al. The value of C-reactive protein as an independent prognostic indicator for disease-specific survival in patients with soft tissue sarcoma: a meta-analysis. *PLoS One*. 2019;14(7):e0219215. doi:10.1371/journal.pone.0219215
- 15. Errani C, Cosentino M, Ciani G, et al. C-reactive protein and tumour diagnosis predict survival in patients treated surgically for long bone metastases. *Int Orthop.* 2021;45(5):1337–1346. doi:10.1007/s00264-020-04921-2
- 16. McMillan DC, Watson WS, O'Gorman P, et al. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. *Nutr Cancer*. 2001;39(2):210–213. doi:10.1207/S15327914nc392_8
- Hirahara N, Matsubara T, Kaji S, et al. Glasgow prognostic score is a better predictor of the long-term survival in patients with gastric cancer, compared to the modified Glasgow prognostic score or high-sensitivity modified Glasgow prognostic score. *Oncotarget*. 2020;11(45):4169–4177. doi:10.18632/oncotarget.27796
- Ando K, Sakamoto S, Saito S, et al. Prognostic value of high-sensitivity modified Glasgow prognostic score in castration-resistant prostate cancer patients who received docetaxel. *Cancers*. 2021;13(4):773. doi:10.3390/cancers13040773
- Spense S, Doonan J, Farhan-Alanie OM, et al. Does the modified Glasgow prognostic score aid in the management of patients undergoing surgery for soft-tissue sarcoma?: An international multicentre study. *Bone Joint J*. 2022;104-B(1):168–176. doi:10.1302/0301-620X.104B1.BJJ-2021-0874. R1
- 20. Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. *Lancet Oncol.* 2016;17(5):671–680. doi:10.1016/S1470-2045(16)00010-3

Journal of Inflammation Research

Dovepress

3899

Publish your work in this journal

The Journal of Inflammation Research is an international, peer-reviewed open-access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis formation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflammation. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/journal-of-inflammation-research-journal

If in DovePress